Global
Regulatory
Strategy

Leaders in Multi-Region Development

Why Strategy Matters

One Program. A Dozen Regulators. It Only Works as One Plan.

Every regional regulatory decision constrains the others: an endpoint FDA accepts that PMDA questions, a comparator EMA expects that doubles your trial, a CMC change filed in one market that triggers variations in thirty. Programs that treat each region as its own project pay for the same work twice and discover the conflicts late, usually inside a review clock. We build one integrated global strategy: which markets, in what order, on what evidence, with every regional requirement mapped back to a single development plan your team can actually execute.

Deciding between FDA-first and parallel filings? The choice compounds with every study you start.

Talk to an Expert
Capabilities

From Target Product Profile to the Last Market Launched.

We build and run global regulatory strategy across the whole arc: deciding where to go, sequencing how to get there, and keeping a dozen regional workstreams pointed at the same product.

Integrated Regulatory Roadmaps

One development plan that satisfies every target region, built from the TPP and mapped to program milestones and funding gates.
Market Entry & Filing Sequencing

Which markets, in what order, and why: filing sequences built on regulatory feasibility, reliance pathways, and commercial reality.
Coordinated Agency Engagement

Scientific advice sequenced across FDA, EMA, MHRA, PMDA, and beyond, so each agency's answer strengthens your position with the next.
Global Expedited Pathways

Breakthrough, PRIME, ILAP, Sakigake, and orphan designations pursued as one campaign instead of regional afterthoughts.
Global Dossier Planning

A core dossier strategy that regionalizes cleanly: CTD content plans, Module 1 variants, and a lifecycle that stays manageable at scale.
Emerging & Secondary Markets

LATAM, APAC, MENA, and Africa registrations through reliance procedures, local representatives, and requirements you learn once, not per market.
Integrated Regulatory Roadmaps

The Plan That Keeps Six Regional Plans From Diverging.

A global roadmap is not six regional plans stapled together. It starts from a target product profile validated against regulatory precedent, defines the single evidence package that satisfies every target agency, and marks the decision points where the program commits: endpoint selection, comparator choice, filing sequence, manufacturing scale. Built early, it prevents the quiet regional divergence that surfaces two years later as a repeated study.

What the Roadmap Covers

  • Target product profile development and precedent validation
  • Integrated development plan across nonclinical, CMC, and clinical
  • Regional requirements mapped to one protocol and evidence set
  • Scenario analysis: FDA-first, EU-first, or parallel submission
  • Regulatory decision points tied to program milestones and funding gates
  • Program-level regulatory risk register with mitigation owners
  • Annual strategy refresh as guidance and precedent move
Market Entry & Filing Sequencing

Where You File Second Matters Almost as Much as Where You File First.

The first approval sets the reference point; the sequence after it determines how fast the rest of the world follows and how much each market costs. We design filing sequences around approval timelines, reliance eligibility, pricing reference effects, and the practical capacity of your team, because a sequence your organization cannot staff is not a strategy, it is a wish list.

How We Sequence

  • Market prioritization: regulatory feasibility against commercial value
  • Filing sequence design with timeline and dependency modeling
  • Reference-country strategy for reliance-based approvals
  • Access Consortium and Project Orbis participation strategy
  • Local clinical data expectations (NMPA, PMDA bridging, CDSCO)
  • Pricing-reference and launch-sequence interaction analysis
  • MAH, local representative, and importer structure planning
Coordinated Agency Engagement

Every Agency Hears the Same Story, in the Order That Helps You.

Scientific advice is a sequence, not a set of independent meetings. Asked in the right order, each agency's answer becomes evidence in the next conversation; asked carelessly, one agency's concern becomes every agency's question. We plan the global advice campaign, keep the data package and positions consistent across regions, and run the individual interactions through our FDA meeting strategy practice and its counterparts for the other authorities.

Engagements We Coordinate

  • Global advice sequencing across FDA, EMA, MHRA, PMDA, and Health Canada
  • Parallel EMA/FDA Scientific Advice and joint procedures
  • Simultaneous National Scientific Advice (SNSA) in Europe
  • Cross-agency consistency control for briefing packages and positions
  • Divergence management when agencies disagree
  • Single global Q&A repository so answers never contradict
  • Post-advice reconciliation into the integrated development plan

Regional teams pulling the program in different directions? Get one strategy before the next protocol locks.

Request a Review
Global Expedited Pathways

Accelerated Everywhere Is a Strategy. Accelerated Somewhere Is an Accident.

Most sponsors chase the FDA designation and treat the rest of the world as follow-up paperwork. The designations interact: orphan status in one region strengthens the case in another, a PRIME acceptance changes what parallel advice is worth, and designation timing determines whether the benefits arrive while they can still shape the program. We run designations as one coordinated campaign with a single evidence narrative behind all of them.

Pathways We Pursue

  • Breakthrough Therapy, Fast Track, and RMAT designations (FDA)
  • PRIME eligibility and application strategy (EMA)
  • ILAP passports and MHRA acceleration (UK)
  • Sakigake and conditional early approval (PMDA)
  • Orphan drug designations across FDA, EMA, and PMDA
  • Accelerated and conditional approval route selection per region
  • Pediatric strategy alignment: PSP and PIP as one plan
Global Dossier Planning

One Core Dossier. Many Regional Faces. Zero Contradictions.

A global filing program lives or dies on its core dossier: the CTD content that stays identical everywhere, the regional layers that adapt cleanly, and the change control that keeps forty registrations telling the same story after every variation. We plan the dossier architecture before the first module is written, so regionalization is assembly rather than rewriting, and lifecycle maintenance stays affordable as the market count grows.

What We Plan

  • Core dossier strategy and CTD content plans across Modules 2 through 5
  • Regional Module 1 requirements and administrative variants
  • Company Core Data Sheet (CCDS) and global labeling strategy
  • Submission content plans with authoring and review timelines
  • eCTD readiness across regional gateways and validation rules
  • Global variation and lifecycle management strategy
  • Post-approval change coordination across all registrations
Emerging & Secondary Markets

The Second Wave of Markets Decides the Product's Real Reach.

After the major approvals, the program's economics depend on how efficiently the next thirty markets follow. Reliance procedures can compress those timelines dramatically, but only if the reference dossier was built with them in mind and someone owns the local mechanics: agents, legalizations, in-country testing, sample requirements. We plan the second wave as deliberately as the first, and coordinate the local partners who execute it.

Markets & Mechanisms

  • LATAM registrations: ANVISA, COFEPRIS, INVIMA, and regional strategy
  • APAC registrations: NMPA, CDSCO, TGA, HSA, MFDS, and ASEAN markets
  • MENA and Africa strategy, including SFDA and WHO-reliant markets
  • Reliance and abridged pathways built on FDA or EMA approvals
  • WHO prequalification and collaborative registration procedures
  • Local representative, agent, and MAH network coordination
  • In-country testing, sample, and legalization logistics planning
Adjacent Capabilities

Beyond the Strategy Document.

A strategy is only as good as the function executing it. Two engagements extend the work: leading your global regulatory function on a fractional basis, and rebuilding the strategy when events have already broken it.

Fractional Global Regulatory Leadership

A Global Head of Regulatory, for the Years Before You Can Hire One.

Most companies need global regulatory leadership years before they can justify the full-time hire. Our senior consultants step in as acting heads of regulatory affairs: setting the strategy, running agency relationships, hiring and mentoring the internal team, and representing regulatory at the board. When the full-time leader arrives, they inherit a working function instead of a backlog.

Included Capabilities

  • Acting VP or Head of Global Regulatory Affairs engagements
  • Regulatory function design, hiring plans, and team mentoring
  • Board, investor, and partner-facing regulatory representation
  • Vendor and CRO regulatory oversight
  • Governance frameworks for regional affiliate decision-making
  • Transition planning and handover to permanent leadership
Strategy Resets & Program Rescue

When the Plan Breaks, Speed of Reset Is the Strategy.

A Complete Response Letter, a failed endpoint, diverging advice between two major agencies: every global program eventually hits an event the original strategy did not price in. We run rapid strategy resets that separate what the event actually changed from what it merely shook, rebuild the filing sequence around the new facts, and give leadership a decision package while there is still time to act on it.

Included Capabilities

  • Post-CRL and post-refusal global strategy reassessment
  • Divergent-advice arbitration: deciding which agency position leads
  • Filing sequence redesign after timeline slips
  • Indication, population, and market re-scoping analysis
  • Investor and board communication support through the reset
  • Re-engagement strategy with the agencies involved
Who You're Working With

Strategists Who Have Filed on Every Continent.

Global strategy fails when it is written by people who have only ever filed in one region. Our teams pair former heads of global regulatory affairs with former agency staff and an in-country network across the major and emerging markets, so the plan reflects how each authority actually behaves.

Former Global Heads of Regulatory

Consultants who have owned worldwide filing programs as sponsors: sequencing launches, defending timelines to boards, and living with the consequences of the strategy they set.

Former Agency Staff Across Regions

Reviewers and assessors from FDA, EMA national authorities, and MHRA who know what each agency treats as precedent, and what it quietly ignores.

In-Country Network

Local regulatory practitioners across LATAM, APAC, MENA, and Africa who handle the mechanics reliance procedures depend on: agents, dossier localization, and authority follow-up.

Modality and Therapeutic Breadth

Small molecule, biologics, cell & gene therapy, devices, diagnostics, and combination products, across oncology, rare disease, immunology, neuroscience, and beyond.

Work With Us

Your Global Strategy Should Exist Before Your Next Protocol Does.

Tell us where the program stands: markets under consideration, advice already received, and the next milestone on the calendar. We'll match you with a senior global strategy lead and respond within one business day. All inquiries are strictly confidential.

Schedule a Call Send a Detailed Inquiry
Insights & News

Thought Leadership on Global Strategy.

Our team's perspectives on multi-region development, filing sequences, and how the major agencies actually diverge: coming soon. In the meantime, reach out directly with a question you'd like to see addressed.

Coming Soon

FDA-First or Parallel: Choosing a Filing Sequence

The variables that actually decide it, and the ones that just feel important.

Coming Soon

Reliance Pathways: The Fastest Route Nobody Plans For

How Access Consortium, Orbis, and WHO reliance compress second-wave timelines.

Coming Soon

When Regional Advice Conflicts, Who Wins?

A framework for deciding which agency position leads the program.